Clinical Trials

Classical hematologyLymphoidOther hematologic neoplasm

28 enrolled

Anemia, Hemolytic, Autoimmune, Burkitt Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT06446128 2025-08-21

A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)

20 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT07048353 2025-07-02

CAR-T，MTD

15 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Lymphoma, Lymphoma, B-Cell

NCT07003178 2025-06-04

A Study to Evaluate the Safety and Clinical Efficacy of STR-P004

30 enrolled

Lymphoma, Non-Hodgkin

NCT06092047 2025-05-16

UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.

CD19-positive Relapsed or Refractory B-cell Malignancies

NCT05651178 2025-01-07

Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients

Lymphoma, Recurrence

NCT06532643 2024-09-19

Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma

Lymphoma

NCT04541108 2024-04-18

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

DermatologicHead & NeckLymphoidSarcoma

15 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Lymphoma, Melanoma, Sarcoma

NCT05979857 2023-11-22

Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase EARLY_PHASE1 Not yet recruiting

72 enrolled

Phase EARLY_PHASE1 Terminated

Lymphoma

NCT03371420 2023-04-18

PET Imaging of Subjects Using 124I-PU-AD

5 enrolled

LymphoidPlasma cell

Alzheimer Disease, Lymphoma, Neoplasms, Plasma Cell

NCT05651191 2022-12-14

To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL

Burkitt Lymphoma

NCT05480501 2022-07-29

Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia

Phase EARLY_PHASE1 Withdrawn

Burkitt Lymphoma, Leukemia

NCT04891718 2022-07-08

CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia

DermatologicHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Lymphoma, Melanoma, Sarcoma

NCT04439721 2021-01-06

γδT

5 enrolled

Leukemia, Leukemia, B-Cell

NCT04626726 2020-11-13

Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation

50 enrolled

Burkitt Lymphoma

NCT04626765 2020-11-13

CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia

50 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03790891 2020-03-13

Treatment of Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy

12 enrolled

Lymphoma, Non-Hodgkin

NCT04191941 2019-12-10

Treatment of Hematological Malignancy With Novel CAR-T Cells.

LymphoidPlasma cell

Burkitt Lymphoma, Multiple Myeloma, Lymphoma, B-Cell

NCT04184414 2019-12-03

The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Mantle-Cell

NCT04156243 2019-11-12

CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies

20 enrolled

Leukemia, B-Cell, Lymphoma, B-Cell

NCT03910842 2019-09-06

Treatment of Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy

12 enrolled

Phase EARLY_PHASE1 Terminated

Leukemia, Lymphoma, Non-Hodgkin

NCT03454243 2019-04-25

TITAN

1 enrolled

DermatologicGenitourinaryLymphoidThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Hodgkin Disease, Melanoma

NCT03690310 2019-01-31

Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

Lymphoma, B-Cell

NCT03824964 2019-01-31

Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

Lymphoma, B-Cell

NCT03692767 2019-01-30

Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma